Hi all. I have been asking around and I decided just to do a few things to make up my mind:
1. I don't see any need for a floating CEO and SB doesn't run any of the businesses. Seems to be strategic position and most of that will probably be dictated by what we have put together - the role is no longer needed.
2. I have phoned a couple of times to speak to him and never got a return call.
3. I have always got return calls from the other directors I know at Interprac before they merged.
4. SB's presentations have really shown a lack of ability in my opinion to outline a cohesive plan. One of the interviews on their own Finance news was very hesitant.
5. Really would much prefer a non-executive chair and for Garry Crole to be CEO as he leads Interprac and has had dealings with Sargon as I understand it. Plus Sargon has purchased the Trustee business from One Vue that was originally the major portion of the Diversa business that Garry Crole was a director of. If I read between the lines then I think he will get us our best shot at building a great business.
6. The director being proposed has a lot of good points just trying to find out more about him. Will post what I get so head to head I think a wealthy and vastly experienced person like him is a better bet for me.
So my vote is to go with the 249. Normally these are not proposed lightly and I will go with it.
All my biased opinions. personal viewpoints and
- Forums
- ASX - By Stock
- Ann: Notice of General Meeting and Proxy Form
SEQ
sequoia financial group ltd
Add to My Watchlist
1.43%
!
35.5¢

Hi all. I have been asking around and I decided just to do a few...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
35.5¢ |
Change
0.005(1.43%) |
Mkt cap ! $43.87M |
Open | High | Low | Value | Volume |
35.5¢ | 35.5¢ | 35.0¢ | $37.20K | 105.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 56039 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.5¢ | 19052 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 56039 | 0.350 |
1 | 2944 | 0.340 |
2 | 2992 | 0.335 |
2 | 13000 | 0.330 |
1 | 1550 | 0.325 |
Price($) | Vol. | No. |
---|---|---|
0.355 | 19052 | 2 |
0.360 | 134902 | 2 |
0.365 | 72540 | 3 |
0.370 | 33513 | 2 |
0.375 | 89000 | 3 |
Last trade - 15.00pm 27/06/2025 (20 minute delay) ? |
Featured News
SEQ (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online